Pages that link to "Q58856133"

The following pages link to Effectiveness of a Mass Immunization Campaign Against Serogroup C Meningococcal Disease in Quebec (Q58856133):

Displaying 43 items.

• The use of supplementary immunisation activities to improve uptake of current and future vaccines in low-income and middle-income countries: a systematic review protocol (Q26864948) (← links)
• The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data (Q30697382) (← links)
• Assessment of factors associated with complete immunization coverage in children aged 12-23 months: a cross-sectional study in Nouna district, Burkina Faso (Q33510443) (← links)
• Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. (Q33769150) (← links)
• Vaccine prevention of meningococcal disease, coming soon? (Q34460367) (← links)
• The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains (Q34500581) (← links)
• Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine (Q34531872) (← links)
• Meningococcal disease serogroup C. (Q35832179) (← links)
• Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research (Q35901353) (← links)
• Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England (Q35923728) (← links)
• BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines (Q36001047) (← links)
• Risk and prevention of meningococcal disease among education workers: A review (Q36170833) (← links)
• The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine (Q36253528) (← links)
• Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study (Q36738155) (← links)
• The changing epidemiology of meningococcal disease in North America 1945-2010. (Q36887966) (← links)
• Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada (Q37421134) (← links)
• Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages (Q37556739) (← links)
• Social welfare and adolescent vaccination programs in the United States: the economic opportunities for a systematic expansion (Q37592054) (← links)
• Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway (Q37597599) (← links)
• The epidemiology of meningococcal disease and the impact of vaccines (Q37706585) (← links)
• Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience (Q37821482) (← links)
• Challenges for development of meningococcal vaccines in infants and children. (Q37857251) (← links)
• Modelling the epidemiology of infectious diseases for decision analysis: a primer (Q37866752) (← links)
• Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. (Q38498875) (← links)
• Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis (Q38631381) (← links)
• Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial (Q40329667) (← links)
• Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years (Q40595860) (← links)
• The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. (Q42204205) (← links)
• Modifiable risk factors for invasive meningococcal disease during an Edmonton, Alberta outbreak, 1999-2002. (Q46628094) (← links)
• Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001. (Q47333329) (← links)
• Comments on the paper “The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data” [P. Rivest, R. Allard, Vaccine 20 (2002) 2533–2536] (Q47916575) (← links)
• Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: A multicountry analysis (Q51154732) (← links)
• Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. (Q53565283) (← links)
• Delivery of Multiple Child and Maternal Health Interventions during Supplementary Immunization Campaign in Rwanda, 2013: Lessons Learnt (Q62486146) (← links)
• Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis (Q64127980) (← links)
• Neisseria meningitidis Carriage during an Outbreak of Serogroup C Disease (Q64134088) (← links)
• Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec (Q74422856) (← links)
• Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease (Q79740329) (← links)
• Meningococcal vaccines (Q80511370) (← links)
• Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age (Q84862846) (← links)
• Implementation and impact of a meningococcal C conjugate vaccination program in 13- to 25-year-old individuals in Galicia, Spain (Q85011949) (← links)
• Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story (Q92309241) (← links)
• Impact and effectiveness of meningococcal vaccines: a review (Q92485381) (← links)